A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-Tacro Tablets Once Daily and Prograf Capsules Twice Daily in Adult De Novo Liver Transplant Patients

Trial Profile

A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-Tacro Tablets Once Daily and Prograf Capsules Twice Daily in Adult De Novo Liver Transplant Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Liver transplant rejection
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Veloxis Pharmaceuticals
  • Most Recent Events

    • 03 Jul 2012 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 03 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jan 2011 Top-line, long-term safety and efficacy data are positive, according to a LifeCycle Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top